Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Bristol-Myers Squibb appears poised to win a big niche in China’s cancer drug market. The company reported Thursday night that their Phase III comparing their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.